G
Exchange
—
Entity type
operating
Fiscal year end
Dec 31
Headquarters
DE
Recent Filings
- SC 13G/A67.3 KBG1 Therapeutics, Inc.Nov 13, 1:14 PM ET·0000935836-24-000655
- 8-K298.5 KBG1 Therapeutics, Inc.Sep 18, 9:18 AM ET·0001193125-24-221120
- SC 13G69.2 KBG1 Therapeutics, Inc.Aug 19, 7:02 PM ET·0000935836-24-000538
- 10-Q6.2 MBG1 Therapeutics, Inc.Aug 8, 4:14 PM ET·0001628280-24-036149
- 8-K2.1 MBG1 Therapeutics, Inc.Aug 8, 6:54 AM ET·0001628280-24-035854
- 8-K865.4 KBG1 Therapeutics, Inc.Aug 7, 9:21 AM ET·0001193125-24-195484
- 8-K956.4 KBG1 Therapeutics, Inc.Jun 24, 6:35 AM ET·0001628280-24-029426
- 8-K174.5 KBG1 Therapeutics, Inc.Jun 14, 4:08 PM ET·0001628280-24-028288
- 10-Q5.7 MBG1 Therapeutics, Inc.May 1, 4:17 PM ET·0001628280-24-019622
- 8-K1.6 MBG1 Therapeutics, Inc.May 1, 6:38 AM ET·0001628280-24-019453
Insiders
10- Avagliano MarkChief Business Officer
- Bailey John E. (Jack) Jr.Director, President and CEO
- ESHELMAN FREDRIC NDirector
- Flowers Cynthia LouiseDirector
- Lee JacksDirector
- Malik RajeshChief Medical Officer
- MUIR GLENN PDirector
- MURDOCK TERRY LChief Operating Officer
- Nicholson Garry ADirector
- Perry AndrewChief Commercial Officer
Tickers
No tickers on record
Addresses
business
700 PARK OFFICES DRIVE SUITE 200
RESEARCH TRIANGLE PARK, NC, 27709
mailing
700 PARK OFFICES DRIVE SUITE 200
RESEARCH TRIANGLE PARK, NC, 27709
Former Names
- G-Zero Therapeutics, Inc.2013-04-18